COSMO Pharmaceuticals N.V. (GB:0RGI)
LSE:0RGI
0RGI Stock Chart & Stats
CHF88.07
CHF1.30(2.05%)
At close: 4:00 PM EST
CHF88.07
CHF1.30(2.05%)
Day’s Range― - ―
52-Week RangeCHF41.65 - CHF129.60
Previous CloseN/A
Volume9.00
Average Volume (3M)2.64K
Market Cap
CHF1.49B
Enterprise ValueCHF1.50B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.8%
Share Statistics
EPS (TTM)-0.09
Shares Outstanding17,543,522
10 Day Avg. Volume3,564
30 Day Avg. Volume2,637
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF135.00Price Target Upside53.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.08
Revenue Forecast (FY)CHF109.67M
Bulls Say, Bears Say
Bulls Say
Very Conservative Balance SheetMinimal debt and substantial equity provide durable financial flexibility: the company can fund R&D, support commercialization or licensing initiatives, and withstand multi-quarter revenue shocks without immediate refinancing. This conservatism preserves optionality for strategic actions and downside protection over months.
Proven Large Cash-generation In Strong YearsThe company has demonstrated the structural ability to generate very strong operating and free cash flow in favorable conditions, showing the business model can self-fund growth and licensing activities. When market/product momentum returns, this capability supports reinvestment, milestone funding, and partner leverage.
Focused Gastroenterology And Licensing ModelA specialist product and licensing mix creates durable competitive positioning: niche clinical expertise aids adoption among gastroenterologists, while licensing and milestone royalties diversify revenue streams and allow leverage of partner commercialization, reducing sole dependence on direct sales over time.
Bears Say
Highly Volatile Revenue And ProfitabilityLarge year-to-year swings in sales and margins undermine forecasting and capital planning. Persistent volatility complicates long-term R&D and commercial investment decisions, reduces predictability for partners and payors, and raises the risk that strong prior-year results are not repeatable across multi-quarter planning horizons.
Recent Collapse In Cash GenerationTransitioning from large positive cash flows to cash burn signals current operations no longer self-fund growth or obligations. Over several months this can force drawdowns of reserves or new financing, constrain R&D and commercialization pacing, and limit strategic flexibility despite a strong balance sheet base.
Return On Equity Deteriorated To NegativeNegative ROE indicates the firm’s equity base is not generating returns, pressuring long-term value creation. If this persists, it can erode investor and partner confidence, challenge dividend or capital allocation policies, and prompt scrutiny of commercial strategy and cost structure across ensuing quarters.
COSMO Pharmaceuticals N.V. News
0RGI FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest share price was CHF41.65 and its highest was CHF129.60 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.49B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 29, 2026 which is in 110 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.092 earnings per share for the quarter, missing the consensus estimate of CHF0.185 by -CHF0.277.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.788 which represents an annual dividend yield of 1.8%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.092 in its last earnings report, missing expectations of CHF0.185. Following the earnings report the stock price went down -7.972%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in GB:0RGI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
0RGI Stock 12 Month Forecast
Average Price Target
CHF135.00
▲(53.29% Upside)
Technical Analysis
Options Prices
Currently, No data available
---